Update shared on10 Aug 2025
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x.
What's in the News
- New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.
- CytoSorb® distinguishes itself with a broad-spectrum, multi-target approach to sepsis, offering benefits like controlling inflammation, reversing shock, protecting blood vessels, and preventing multiple organ failure.
- CytoSorbents is pursuing regulatory approval for DrugSorb-ATR in the U.S. and Canada; actively engaged in an FDA supervisory review process following De Novo denial, and Health Canada review is ongoing amid backlog delays.
- Real-world data presented at EuroPCR 2025 highlight the effectiveness of CytoSorbents technology in reducing bleeding severity during urgent CABG surgery for patients on ticagrelor.
- Cytosorbents Corporation was recently added to multiple Russell indices, including the Microcap, Microcap Growth, 3000E, 3000E Growth, reflecting increased market visibility.
Valuation Changes
Summary of Valuation Changes for Cytosorbents
- The Consensus Analyst Price Target has significantly risen from $5.00 to $7.00.
- The Net Profit Margin for Cytosorbents has significantly risen from 6.70% to 12.34%.
- The Future P/E for Cytosorbents has significantly fallen from 106.88x to 74.11x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.